Literature DB >> 1225487

Serum disappearance and catabolism of homologous immunoglobulin fragments in rats.

W P Arend, F J Silverblatt.   

Abstract

The serum disappearance, metabolic clearance and whole body catabolism of homologous immunoglobulin fragments were studied in rats. The rapid disappearance of Fab fragments from serum in normal animals was no longer present after nephrectomy. In contrast, the serum disappearance curve of Fc fragments was not altered by nephrectomy. The results of three different experiments, however, indicated that similar to Fab fragments, some Fc fragments underwent filtration and degradation in the kidneys. First, the amount of intact Fc fragments excreted in the first day after injection increased from 6% of the injected dose in normal rats to 17% in rats pretreated with sodium maleate. Secondly, nephrectomy eliminated the rapid phase of whole body catabolism of inected Fc fragments. Thirdly, auto-radiographic studies showed localization of Fc fragments in the renal proximal tubule cells in the first 3 hr after injection. An identical localization was seen with Fab fragments. These results support the conclusion that removal from circulation by glomerular filtration and subsequent reabsorption and degradation in proximal tubule cells represent the major mechanism for catabolism of Fab fragments. Although some Fc fragments undergo the same fate, most injected Fc fragments equilibrate with unknown sites where they are possibly bound and made unavailable for filtration in the kidneys.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1225487      PMCID: PMC1538449     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION.

Authors:  J L FAHEY; A G ROBINSON
Journal:  J Exp Med       Date:  1963-11-01       Impact factor: 14.307

2.  High specific activity iodination of gamma-globulin with iodine-131 monochloride.

Authors:  R W HELMKAMP; R L GOODLAND; W F BALE; I L SPAR; L E MUTSCHLER
Journal:  Cancer Res       Date:  1960-11       Impact factor: 12.701

3.  The hydrolysis of rabbit y-globulin and antibodies with crystalline papain.

Authors:  R R PORTER
Journal:  Biochem J       Date:  1959-09       Impact factor: 3.857

4.  Proteinuria.

Authors:  H O Heinemann; T M Maack; R L Sherman
Journal:  Am J Med       Date:  1974-01       Impact factor: 4.965

5.  The catabolism of human G immunoglobulins of different heavy chain subclasses. 3. The catabolism of heavy chain disease proteins and of Fc fragments of myeloma proteins.

Authors:  H L Spiegelberg; B G Fishkin
Journal:  Clin Exp Immunol       Date:  1972-04       Impact factor: 4.330

6.  Absorption of I-125-labeled homologous albumin by rat kidney proximal tubule cells. A study of microperfused single proximal tubules by electron microscopic autoradiography and histochemistry.

Authors:  A B Maunsbach
Journal:  J Ultrastruct Res       Date:  1966-06

7.  The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments.

Authors:  R D Wochner; W Strober; T A Waldmann
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

8.  Renal handling of low molecular weight proteins. I. L-Chain metabolism in experimental renal disease.

Authors:  R P Mogielnicki; T A Waldmann; W Strober
Journal:  J Clin Invest       Date:  1971-04       Impact factor: 14.808

9.  THE CATABOLISM OF HOMOLOGOUS AND HETEROLOGOUS 7S GAMMA GLOBULIN FRAGMENTS.

Authors:  H L SPIEGELBERG; W O WEIGLE
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

  9 in total
  11 in total

1.  Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert L Vessella
Journal:  Bioconjug Chem       Date:  2011-05-05       Impact factor: 4.774

2.  Development trends for therapeutic antibody fragments.

Authors:  Aaron L Nelson; Janice M Reichert
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

Review 3.  Impact of physiochemical properties on pharmacokinetics of protein therapeutics.

Authors:  Rajan Swami; Aliasgar Shahiwala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-14       Impact factor: 2.441

4.  Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG.

Authors:  K V Toyka; B Löwenadler; K Heininger; U A Besinger; K L Birnberger; A Fateh-Moghadam; E Heilbronn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-09       Impact factor: 10.154

5.  Immunoglobulin G1 Fc in colostral whey.

Authors:  K Nielsen; J Stiller; B Sowa
Journal:  Can J Comp Med       Date:  1984-10

6.  A comparison of iodine and indium labelled anti CEA intact antibody, F(ab)2 and Fab fragments by imaging tumour xenografts.

Authors:  S M Andrew; A C Perkins; M V Pimm; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1988

7.  Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.

Authors:  T W Smith; B L Lloyd; N Spicer; E Haber
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

Review 8.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

9.  Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.

Authors:  Eric C Peterson; Elizabeth M Laurenzana; William T Atchley; Howard P Hendrickson; S Michael Owens
Journal:  J Pharmacol Exp Ther       Date:  2008-01-11       Impact factor: 4.030

10.  Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent.

Authors:  C Motta-Hennessy; S A Eccles; C Dean; G Coghlan
Journal:  Eur J Nucl Med       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.